Skip to main content
Article thumbnail
Location of Repository

Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation

By Graeme O'Boyle, Christopher Fox, Hannah Walden, Joseph Willet, Emily Mavin, Dominic Hine, Jeremy Palmer, Catriona Barker, Christopher Lamb, Simi Ali and John Kirby

Abstract

The recruitment of T lymphocytes during diseases such as rheumatoid arthritis is regulated by stimulation of the chemokine receptors expressed by these cells. This study was designed to assess the potential of a CXCR3-specific small-molecule agonist to inhibit the migration of activated human T cells toward multiple chemokines. Further experiments defined the molecular mechanism for this anti-inflammatory activity. Analysis in vitro demonstrated agonist induced internalization of both CXCR3 and other chemokine receptors coexpressed by CXCR3+ T cells. Unlike chemokine receptor-specific antagonists, the CXCR3 agonist inhibited migration of activated T cells toward the chemokine mixture in synovial fluid from patients with active rheumatoid arthritis. A humanized mouse air-pouch model showed that intravenous treatment with the CXCR3 agonist prevented inflammatory migration of activated human T cells toward this synovial fluid. A potential mechanism for this action was defined by demonstration that the CXCR3 agonist induces receptor cross-phosphorylation within CXCR3-CCR5 heterodimers on the surface of activated T cells. This study shows that generalized chemokine receptor desensitization can be induced by specific stimulation of a single chemokine receptor on the surface of activated human T cells. A humanized mouse model was used to demonstrate that this receptor desensitization inhibits the inflammatory response that is normally produced by the chemokines present in synovial fluid from patients with active rheumatoid arthritis

Topics: A100, C900
Publisher: National Academy of Sciences
Year: 2012
OAI identifier: oai:nrl.northumbria.ac.uk:5633

Suggested articles

Citations

  1. (2005). A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation.
  2. Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs
  3. (2009). Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12.
  4. (2011). Characterization of the chemokine CXCL11-heparin interaction vivo.
  5. (2009). CXCR3 antagonism impairs the development of donorreactive, IFN-gamma-producing effectors and prolongs allograft survival.
  6. (2001). Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis.
  7. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.